InfuSystem initiated with a Buy at Roth Capital

Roth Capital analyst Kyle Bauser initiated coverage of InfuSystem (INFU) with a Buy rating and $12 price target InfuSystem operates two key segments – Patient Services and Device Solutions – and the company’s ability to automate billing, patient records, and pump tracking allows it to serve a larger base without linearly scaling headcount, the analyst tells investors. The firm believes the company can drive further margin expansion from more efficient operations and additional scale, the analyst added.